Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key

Published:2021-03-23 Issue: Volume: Page:1-6
ISSN:1784-3286
Container-title:Acta Clinica Belgica
language:en
Short-container-title:Acta Clinica Belgica

Author:

Saerens Michael¹²^ORCID,Kruse Vibeke²³^ORCID,Lybaert Willem²^ORCID

Affiliation:

1. Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium

2. Department of Medical Oncology, AZ Nikolaas, Sint-Niklaas, Belgium

3. Department of Internal Medicine and Pediatrics, Faculty of Health Sciences, University of Ghent, Ghent, Belgium

Funder

no financial support for the research, authorship, and/or publication of this article

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17843286.2021.1903662

Reference35 articles.

1. The blockade of immune checkpoints in cancer immunotherapy

2. Cancer immunotherapy using checkpoint blockade

3. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

4. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

5. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methylprednisolone/nivolumab/sunitinib;Reactions Weekly;2022-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP